Screening haemostasis - Looking for global assays: The overall haemostasis potential (OHP) method - A possible tool for laboratory investigation of global haemostasis in both hypo- and hypercoagulable conditions

Current Vascular Pharmacology

Volumn 6, Issue 3, 2008, Pages 173-185

  Antovic, Aleksandra ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Clot lysis time (CLT); Global haemostatic assay; Overall coagulation potential (OCP); Overall fibrinolysis potential (OFP); Overall haemostatic potential (OHP); Screening test

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8 INHIBITOR; CALCIUM CHLORIDE; DALTEPARIN; HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7A; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; BLOOD CLOT LYSIS; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYSIS; GLOBAL HAEMOSTASIS ASSAY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPOCOAGULABILITY; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LABORATORY TEST; MONOTHERAPY; OVERALL COAGULATION POTENTIAL; OVERALL FIBRINOLYSIS POTENTIAL; OVERALL HAEMOSTASIS POTENTIAL; PATIENT MONITORING; PREECLAMPSIA; PROTEIN AGGREGATION; REVIEW; SCREENING TEST; SENSITIVITY ANALYSIS; SPECTROPHOTOMETRY; STROKE; THROMBOCYTE AGGREGATION; THROMBOPHILIA; THROMBOSIS; VALIDITY; VASCULAR DISEASE; VASCULAR SURGERY; BIOASSAY; BLOOD; BLOOD CLOTTING DISORDER; METHODOLOGY; PHYSIOLOGY; REPRODUCIBILITY;

ANTICOAGULANTS; BIOLOGICAL ASSAY; BLOOD COAGULATION DISORDERS; FACTOR VIIA; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; THROMBOSIS;

EID: 53449084774     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108784912028     Document Type: Review

References (81)

1. Roberts HF, Monroe DM, Oliver JA, Chang JZ, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998; 4: 331-4.
2. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.
3. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
4. Hoffman M, Monroe DM. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006; 26:41-8.
5. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-2.
6. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 1964; 202: 498-99.
7. Wiman B, Colten D. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549-50.
8. Bajzar L, Manuel R, Neisheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270:1477-84.
9. Antovic A. Determination of overall hemostasis potential and fibrin gel permeability: method development and application in research and in clinical materials (PhD thesis), Karolinska Institute, Stockholm, Sweden 2004.
10. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-47.
11. Quick AJ. The prothrombin time in haemophilia and obstructive jaundice. J Biol Chem 1935; 109: 73-4.
12. Galanakis DK. Fibrinogen anomalies and disease. A clinical update. Hematol Oncol Clin North Am 1992; 6: 1171-87.
13. Erban SB, Kinman JL, Schwartz JS. Routine use of the prothrombin and partial thromboplastin times. JAMA 1989; 262: 2428-32.
14. Kitchen S, Cartwright I, Woods TA, Jennings I, Preston FE. Lipid composition of seven APTT reagents in relation to heparin sensitivity. Br J Haematol 1999; 106:801-8.
15. Ray MJ. An artefact related to the ratio of sample volume to the blood collection vial size which effects the APTTs of specimens taken to monitor heparin therapy. Thromb Haemost 1991; 66:387-8.
16. Hillarp A, Egberg N, Nordin G, Stigendal L, Fagerberg I, Lindahl TL. Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation. A three-year follow-up from the Swedish national external quality assessment scheme. Thromb Haemost 2004; 91:300-7.
17. Brummel KE, Paradis SG, Butenas S, Man KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
18. Mann KG, Brummel K, Butenas S. What is all thrombin for? J Thromb Haemost 2003; 1: 1504-14.
19. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
20. Hemker HC, Giesen PL, Ramjee M, Wagenvoord I, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma, Thromb Haemost 2000; 83: 589-91.
21. Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
22. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
23. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-34.
24. Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocquetau M, Massardo L et al. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 2006; 95: 94-9.
25. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
26. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62.
27. Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, et al. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma-a study in human volunteers. Thromb Haemost 1994; 72: 705-12.
28. Al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004: 2: 1395-401.
29. Wegert W, Graff J, Kaiser D, Breddin HK, Klinkhardt U, Harder S. Effects of antiplatelet agents on platelet-induced thrombin generation. Int J Clin Pharmacol Ther 2002; 40:135-41.
30. Bostrom SL, Hansson GF, Kjaer M, Sarich TC. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis 2003; 14: 457-62.
31. Eichinger S, Weltermann A, Philipp K, Hafner E, Kaider A, Kittl EM, et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 1999; 82: 1232-6.
32. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
33. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
34. Kyrle PA, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
35. Faber CG, Lodder J, Kessels F, Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol Haemost Thromb 2003; 33: 52-8.
36. Hartert H. Thrombelastography, a method for physical analysis of blood coagulation. Z Gesamte Exp Med 1951; 117: 189-203.
37. Calatzis AN, Fritzsche P, Kling M. A new technique for fast and specific coaglulation monitoring. Eur Surg Res 1996; 28: S1(89).
38. Chandler WL. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 1995; 21 (Suppl 4): 1-6.
39. Vorweg M, Hartmann B, Knuttgen D, Jahn MC, Doehn M. Management of fulminant fibrinolysis during abdominal aortic surgery. J Cardiothorac Vasc Anesth 2001; 15: 764-7.
40. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-9.
41. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9: 168-73.
42. Oshita K, Az-ma T, Osawa Y, Yuge O. Quantitative measurement of thromboelastography as a function of platelet count. Anesth Analg 1999; 89: 296-9.
43. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 Suppl 1:1-6.
44. Hobson AR, Agarwaia RA, Swallow RA, Dawkins KD, Curzen NP. Thrombelastography: current clinical applications and its potential role in interventional cardiology. Platelets 2006; 17:509-18.
45. Sorensen B, Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 2006; 96:446-53.
46. Hvitfeldt Poulson L, Christiansen K, Sorensen B, Ingerslev J. Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients. Scand J Clin Lab Invest 2006; 66:329-36.
47. O'Donnell J, Riddell A, Owens D, Handa A, Pasi J, Hamilton G, et al. Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. Blood Crag Fibrinoly 2004; 15: 207-11.
48. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 1:, 2102-10.
49. Vorweg M, Hartmann B, Knuttgen D, Jahn MC, Doehn M. Management of fulminant fibrinolysis during abdominal aortic surgery. J Cardiothorac Vasc Anesth 2001; 15: 764-7.
50. Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002; 87:436-41.
51. Su Z, Braun PJ, Klemp KF, Baker KR, Thames EH, Ortel TL. Abnormal optical waveform profiles in coagulation assays from patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis 2002; 13: 7-17.
52. Toh CH. APTT revisited: detecting dysfunction in the hemostatic system through waveform analysis. Thromb Haemost 1999; 82:684-7.
53. Downey C, Kazmi R, Tob CH. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol 1997; 98: 68-73.
54. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot waveform analysis. Semin Hematol 2004; 41(1 Suppl 1): 125-31.
55. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-66.
56. Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994; 269: 23367-73.
57. Holmes MB, Schneider DJ, Hayes MG, Sobel BE, Mann KG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 2000; 102: 2051-7.
58. He S, Bremme, Blomback M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res 1999; 96: 145-56.
59. He S, Antovic A, Blomback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma II. Modifications for use in routine laboratories land research work. Thromb Res 2001; 103: 355-61.
60. Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmstrom M, He S. Possibility of detecting different hypocoagulable states with a global assay of Overall Haemostasis Potential in plasma. Blood Coag Fibrinoly 2005; 6:585-96.
61. Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen NH, Jorneskog G, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type 1 diabetes mellitus with and without microvascular complications Blood Coag Fibrinolys 2003; 14: 551-6.
62. Anzej S, Bozic M, Antovic A, Peternel P, Gaspersic N, Rot U, et al. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. Thromb Res 2007; 120:39-46.
63. Rooth E, Waller NH, Antovic A, von Arbin M, Kaponides G, Wahlgren N, et al. Thrombin Activatable -Fibrinolysis Inhibitor (TAFI) and its relationship to fibrinolysis and inflammation during the acute and chronic phase of ischemic stroke. Blood Coag Fibrinolys 2007; 18:365-370.
64. Antovic JP, Rafik Hamad R, Antovic A, Blomback M, Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Thromb Haemost 2002; 88: 644-7.
65. Antovic A, Blomback M, Bremme K, Van Rooijen M, He S. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost 2003; 1: 2531-5.
66. Andresen MS, Abildgaard U, Liestol S, Sandset PM, Mowinckel MC, Odegaard OR, et al. The ability of three global plasma assays to recognize thrombophilia. Thromb Res 2004; 113: 411-7.
67. Andresen MS, Iversen N, Abildgaard U. Overall haemostasis potential assays performed in thrombophilic plasma: the effect of pre-activating protein C and antithrombin. Thromb Res 2002; 108: 323-8.
68. Antovic JP, Antovic A, Sten-Linder M, Wramsby M, Blomback M. Overall hemostatic potential (OHP) assay - a possible tool for determination of prothtrombotic pattern in FXII deficiency. J Thromb Haemost 2004; 2: 2058-60.
69. Curnow JL, Morel-Kopp MC, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall haemostasis potential assay. J Thromb Haemost 2007; 5: 528-34.
70. Amovic JP, Antovic A, He S, Tengborn L,,Blomback M. Overall haemostatic potential (OHP) method can be used for estimation of thrombin activatable fibrinolysis inhibitor (TAFI) dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to FVIII. Haemophilia 2002; 8: 781-6.
71. Antovic JP, Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost 2003; 90: 620-7.
72. Von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clot from fibrinolysis. Blood 1995; 86: 3035-42.
73. Antovic A, Blomback M, Bremme K He S. The assay of overall haemostasis potential used to monitor low molecular mass (weight) heparin, dalteparin treatment in pregnant women with previous thromboembolism. Blood Coag Fibrinolys 2002; 13: 181-186.
74. Morel-Kopp MC, Curnow J, Aboud M, Coyle L, Ward CM. Discrepancies between the overall coagulation potential (OCP) assay and international normalised ratio (INR) in warflarin treated patients. Poster presentation XX ISTH Congress, Sydney 2005.
75. Vedin J, Antovic A, Ericsson A, Vaage J. Hemostasis in off-pump compared to on-pump coronary artery bypass grafting: a prospective, randomized study. Ann Thorac Sing 2005; 80: 586-93.
76. Kramkrowski K, Mogielnicki A, Chabielska E, Cylwik D, Buczko W. The effect of 'tissue' and 'plasma' angiotensin converting enzyme inhibitors on overall haemostatic potentials in rats. Thromb Res 2006; 117:557-61.
77. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W, Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 2005; 93: 1069-76.
78. Chabielska E, Mogielnicki A, Kramkowski K, Buezko W, Antithrombotic effect of captopril and enalapril in old rats. Pharmacol Rep 2005; 57: 135-7.
79. He S, Zhu K, Skeppholm M, Veldin J, Svensson J, Egberg N, et al. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost 2007; 98:871-82.
80. Choudhury A, Chung I, Blann AD, Lip GY. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest. 2007; 131:809-15.
81. Cohen Z, Gonzales RF, Davis-Gorman GF, Copeland JG, McDonagh PF. Thrombin activity and platelet microparticle formation are increased in type 2 diabetic platelets: a potential correlation with caspase activation. Thromb Res 2002; 107:217-21.